Lisinopril Market Overview
The global lisinopril market was valued at USD 1.6 billion in 2024 and is expected to grow from USD 1.7 billion in 2025 to USD 2.5 billion by 2035, registering a CAGR of 4.2% during the forecast period from 2026 to 2035. Rising hypertension prevalence, an expanding aging population, increasing healthcare expenditure, and growing demand for affordable generic medicines are supporting market expansion.
North America is expected to remain the leading regional market, valued at USD 700 million in 2024 and projected to reach USD 1.0 billion by 2035. Among applications, hypertension represented the largest segment, valued at USD 850 million in 2024 and expected to reach USD 1.2 billion by 2035. Tablets remain the most prevalent formulation because of their convenience and ease of administration, while oral solutions and injectables serve specific patient and acute-care requirements.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/reports/lisinopril-market
Key Companies in the Lisinopril Market
Torrent Pharmaceuticals
Pfizer
Teva Pharmaceuticals
Sandoz
Mylan
Apotex
Lupin Pharmaceuticals
Aurobindo Pharma
Zydus Cadila
Hikma Pharmaceuticals
Sun Pharmaceutical Industries
Cipla
The market is being driven by the increasing prevalence of hypertension and cardiovascular diseases, particularly among aging populations. Growing healthcare awareness is supporting demand for antihypertensive treatments, while the shift toward generic lisinopril products is improving affordability and accessibility. Advances in drug manufacturing and delivery systems, including sustained-release formulations, are also creating opportunities to improve patient compliance.
The Lisinopril Market is segmented by application, formulation type, distribution channel, dosage strength, and region. Applications include hypertension, heart failure, diabetic kidney disease, and myocardial infarction. Formulation types comprise tablets, oral solutions, and injectables, while distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Dosage strengths covered include 2.5 mg, 5 mg, 10 mg, and 20 mg.
Recent Developments and Market Trends:
Sun Pharmaceutical Industries announced a strategic partnership with Sandoz in February 2025 to co-develop and manufacture generic lisinopril tablets for the U.S. and European markets.
Cipla announced a distribution agreement in May 2024 to supply lisinopril and other cardiovascular generic medicines under a multi-year contract.
Hikma Pharmaceuticals announced a major contract win with a European national payer in June 2025 to secure long-term lisinopril tablet supplies.
Generic lisinopril products are gaining market traction as patent expirations and competitive pricing improve accessibility.
Advancements in drug delivery systems and sustained-release formulations are supporting improved treatment convenience and patient adherence.
Telemedicine and digital health platforms are creating additional opportunities for medication management and adherence support.
Reasons to Buy the Report:
Understand the current market size, growth trajectory, and forecast of the global Lisinopril Market through 2035.
Analyze key segments based on application, formulation type, distribution channel, dosage strength, and region.
Evaluate regional opportunities across North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
Identify major companies and understand their competitive positioning in the global lisinopril market.
Assess the impact of rising hypertension prevalence, generic competition, aging populations, and healthcare expenditure.
Understand emerging opportunities associated with advanced formulations, digital health, telemedicine, and expansion into emerging markets.
Future Outlook:
The global Lisinopril Market is expected to maintain steady growth through 2035 as hypertension and cardiovascular diseases continue to drive demand for effective blood-pressure management. Rising healthcare access, increasing adoption of generic medicines, expanding geriatric populations, and advances in formulation technologies are expected to support market development. Growing demand across emerging economies and the integration of digital health solutions for treatment adherence are likely to create additional opportunities for pharmaceutical companies.
➤➤Explore Our Latest Related Reports:
